Publications by authors named "Mitchell A deLong"

Claim this Profile
E
Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility.
Heeren M Gordhan, Steven T Miller, Daphne C Clancy, Maria Ina, Alan V McDougal, Mitchell A deLong

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates.
Jill Sturdivant, Stuart S Williams, Maria Ina, Meredith Weksler, Alan McDougal, Mitchell A deLong

J Ocul Pharmacol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel.
Tyler Bagué, Ayushi Singh, Rajanya Ghosh, Hannah Yoo, Curtis Kelly, Mitchell A deLong

Front Ophthalmol (Lausanne)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
Cheng-Wen Lin, Bryan Sherman, Lori A Moore, Carmen L Laethem, Da-Wen Lu, Mitchell A deLong

J Ocul Pharmacol Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
Jill M Sturdivant, Susan M Royalty, Cheng-Wen Lin, Lori A Moore, Jeffrey D Yingling, Mitchell A deLong

Bioorg Med Chem Lett· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DeoxyArbutin and its derivatives inhibit tyrosinase activity and melanin synthesis without inducing reactive oxygen species or apoptosis.
Smita Chawla, Kalla Kvalnes, Mitchell A deLong, Randall Wickett, Prashiela Manga

J Drugs Dermatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent.
Saja H Hamed, Penkanok Sriwiriyanont, Mitchell A deLong, Marty O Visscher, R Randall Wickett

J Cosmet Sci· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency.
Raymond E Boissy, Marty Visscher, Mitchell A DeLong

Exp Dermatol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis.
David Lindsey Soper, Yili Wang, Biswanath De, Mitchell Anthony deLong, Michelle Jeanine Dirr

Adv Exp Med Biol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutathione, S-substituted glutathiones, and leukotriene C4 as substrates for peptidylglycine alpha-amidating monooxygenase.
Laura Aaron Miller, Laura E Baumgart, Geoffrey H Chew, Mitchell A deLong, Lamar C Galloway

Arch Biochem Biophys· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis